1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

A Year Of Change: Looking Back At Francis’ First Year At Teva

Teva’s CEO, In Charge For A Year, Has Laid Clear Its More Innovative Ambitions

 
• By Dean Rudge

As part of a Generics Bulletin series focusing on some of the industry’s biggest players, we look at the changing landscape at Teva in 2023, spearheaded by the appointment of its CEO Richard Francis.

Teva logo outside company building
• Source: Shutterstock

“Does there come a point where the company has to think differently? Maybe thinking about investment levels differently or how to run the business differently?” Teva’s CEO Richard Francis was asked in January, just ten days after the former Biogen and Sandoz exec took up the role.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

Regulatory Recap: UK To Capture £1bn Savings With Framework For Best-Value Biologics

 
• By Urtė Fultinavičiūtė

Generics Bulletin reviews global regulatory developments across the world.